We are True Dose, committed to advancing precision medicine through innovative at-home blood sampling technology.

Our story began in 2012, when two of our founders were involved in groundbreaking clinical studies focused on the correlation between drug concentration and the effectiveness of breast cancer treatments. Their research demonstrated that personalized dosing, guided by specific biomarkers in the blood, could significantly improve treatment outcomes compared to the outdated, one-size-fits-all approach based on Body Surface Area (BSA), a method over a century old.

Recognizing the high costs and logistical challenges of traditional blood sampling—requiring patients to travel to distant labs and adhere to strict lab schedules—our founders envisioned a more accessible solution. This vision led to the development of a revolutionary at-home blood sampling kit, starting in 2018. Our goal was to create a tool that would allow patients to measure drug concentrations conveniently at home and send samples via standard postal services for analysis.

After extensive development and validation, True Dose was founded in 2023 with a patented technology that combines simplicity with precision. Our at-home blood sampling kit not only provides accurate measurements but also supports personalized dosing strategies, enhancing the chances of effective treatment while reducing the risks of relapse, toxicity, and side effects.

At True Dose, we are passionate about making personalized medicine accessible and efficient, transforming the way treatments are managed and ultimately improving patient outcomes.

True Dose

Org chart

Teams

Offices